Immune cell combo shows promise for Hard-to-Treat gynecologic cancers
NCT ID NCT07434284
First seen Mar 04, 2026 · Last updated May 15, 2026 · Updated 9 times
Summary
This early-phase study tests a new treatment that combines specially grown immune cells (tumor-specific T cells) with standard immunotherapy for people with advanced gynecologic cancers like ovarian, cervical, or endometrial cancer. The goal is to see if the combination is safe and can shrink tumors. About 5 to 20 patients who have not responded to standard treatments will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED GYNECOLOGICAL CANCERS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
The Obstetrics and Gynecology Hospital of Fudan University
RECRUITINGShanghai, Shanghai Municipality, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.